FDA
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $436 at Canaccord
-
-
-
-
-
-
-
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
-
-
-
-
-
-
-
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
-
-
-
-
-
-
-
VERTEX presents data on cystic fibrosis drugs at conference
-
-
-
-
-
-
-
Vertex Announces Key Advancements Across Kidney Portfolio
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $478 at H.C. Wainwright
-
-
-
-
-
-
-
Vertex (VRTX) PT Raised to $462 at Bernstein SocGen Group
-
322,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

